GlassScriptPhysician profile
Milad Chrieki
NPI 1184708216
$4,827.15
in general payments reported to CMS, 2019-2025
34 companies · $820 in 2025
The $820 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $742 · 2020: $474 · 2021: $713 · 2022: $691 · 2023: $853 · 2024: $535 · 2025: $820.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,208.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,207.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $706.56 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Amarin Pharma, INC. | $650.69 | 2019-2021 | |
| Novo Nordisk INC | $605.59 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $373.51 | 2019-2024 | Arexvy, Shingrix |
| Lilly USA, LLC | $317.72 | 2021-2025 | Mounjaro |
| Abbott Laboratories | $281.52 | 2021-2025 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $238.96 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Astellas Pharma US INC | $193.49 | 2023-2024 | Veozah, Myrbetriq |
| Boston Scientific Corporation | $167.13 | 2022-2025 | Watchman Flx |
| Corcept Therapeutics | $156.61 | 2025 | Korlym |
| Verastem, INC. | $125.01 | 2019 | |
| Esperion Therapeutics, INC. | $119.93 | 2020-2021 | |
| Amgen INC. | $113.45 | 2021-2025 | Repatha, Otezla, Evenity |
| Sanofi Pasteur INC. | $85.50 | 2019-2023 | |
| Mylan Specialty L.P. | $83.27 | 2019 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $65.45 | 2023-2025 | |
| Avvisto Therapeutics, LLC | $60.50 | 2024-2025 | Cycloset |
| Gilead Sciences, INC. | $55.10 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $54.57 | 2022-2025 | |
| Viiv Healthcare Company | $40.70 | 2024 | Apretude |
| Exact Sciences Corporation | $40.38 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Grifols USA, LLC | $38.99 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $37.51 | 2019-2025 | Ajovy |
| Biohaven Pharmaceutical Holding Company LTD. | $34.38 | 2022 | |
| Idorsia Pharmaceuticals US INC | $26.91 | 2022-2023 | Quviviq |
| Phadia US INC. | $23.86 | 2024 | Immunocap |
| Inspire Medical Systems, INC. | $22.88 | 2025 | Inspire |
| Abbvie INC. | $18.02 | 2024 | |
| Almatica Pharma LLC | $17.28 | 2022 | |
| Seqirus USA INC | $16.40 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $15.43 | 2021 | |
| Janssen Pharmaceuticals, INC | $13.68 | 2019 | |
| Linus Health, INC. | $13.41 | 2023 | |
| Kowa Pharmaceuticals America, INC. | $12.76 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Milad Chrieki listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.